Relative Bioavailability of BI 1810631 as Two Different Oral Formulations Given as Single Doses and Investigation of the Effects of Food and Multiple-dose Rabeprazole on the Pharmacokinetics of Single-dose BI 1810631 Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Four-way Crossover Trial)
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Zongertinib (Primary) ; Rabeprazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2022 Status changed from not yet recruiting to recruiting.